logo

For the Inventor, By the Inventor

Mumbai, India

Lupin, Inc.

USPTO Granted Patents = 159

% Expired Patents = 58.5



Trademarks = 24

Forward Citations = 243

Loading Chart...
Loading Chart...

343 inventors (with patents filed for the assignee):

goldMedal Rajender Kumar Kamboj (44 out of 48 patents)

silverMedal Venkata Poornapragnacharyulu Palle (39 out of 106 patents)

bronzeMedal Girij Pal Singh (31 out of 32 patents)

4.  Neelima Sinha (22 out of 31 patents)

5.  Shirishkumar Kulkarni (13 out of 14 patents)

6.  Navnath Popat Karche (12 out of 12 patents)

7.  David Palling (10 out of 15 patents)

8.  Helen S Pentikis (9 out of 10 patents)

9.  Carol J Braun (9 out of 10 patents)

10.  Makarand Krishnakumar Avachat (9 out of 9 patents)

11.  Richard Holl (8 out of 8 patents)

12.  Harshal Jahagirdar (8 out of 8 patents)

13.  Sanjeev Anant Kulkarni (8 out of 15 patents)

14.  Anil Kashiram Hajare (8 out of 8 patents)

15.  Prathap Sreedharan Nair (8 out of 9 patents)


Core Competencies:
Pharmaceutical Compositions
PRMT5 Inhibitors
Controlled Release
Inhaler
Chromane Compounds
Secnidazole
HIV Integrase Inhibitors
Vitamin B12
Oxazoline Derivatives
Bepotastine
Calcium Sensing Receptor
Sodium Channel Modulators

159 patents:

1. 12679849 - Macrocyclic compounds as STING agonists (2026-07-14),
2. 12673054 - Substituted nucleoside analogs as PRMT5 inhibitors (2026-07-07),
3. 12479858 - Macrocyclic compounds as sting agonists and methods and uses thereof (2025-11-25),
4. 12465565 - Pharmaceutical compositions of raltegravir (2025-11-11),
5. 12447152 - Pharmaceutical combination of PRMT5 inhibitors (2025-10-21),
6. 12435066 - Substituted tricyclic compounds (2025-10-07),
7. 12421204 - Process for preparing chroman compounds (2025-09-23),
8. 12391695 - PRMT5 inhibitors (2025-08-19),
9. D1085407 - Applicator for implantable drug delivery (2025-07-22),
10. D1085406 - Applicator for implantable drug delivery (2025-07-22),
11. 12344592 - Methods, processes and intermediates for preparing chroman compounds (2025-07-01),
12. D1058364 - Tray (2025-01-21),
13. 12124920 - Event status apparatuses and related devices, systems, and methods (2024-10-22),
14. 11952380 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2024-04-09),
15. 11684607 - Secnidazole for use in the treatment of bacterial vaginosis (2023-06-27),
Company Overview
Lupin, Inc., headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical compositions. The company specializes in innovative technologies such as PRMT5 inhibitors and controlled release formulations, alongside therapeutic areas including HIV integrase inhibitors and treatments involving chromane compounds and secnidazole. Lupin is committed to enhancing healthcare through its advanced inhaler technologies and essential vitamins like Vitamin B12.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Lupin, Inc. USPTO Patent Assignee Logo
159 Patents

#5 in Mumbai

#11 in India

#5,182 in the World

Mumbai, IN
Mumbai, India

Lupin, Inc.

Forward Citations = 243

343 inventors:

goldMedal Rajender Kumar Kamboj (44 out of 48 patents)

silverMedal Venkata Poornapragnacharyulu Palle (39 out of 106 patents)

bronzeMedal Girij Pal Singh (31 out of 32 patents)

4.  Neelima Sinha (22 out of 31 patents)

5.  Shirishkumar Kulkarni (13 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lupin, Inc.. Retrieved from https://idiyas.com/company/lupin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…